In the field of formation, innovation, not only in content, but also in the formats, is a point that has not to be overlooked.The Boehringer Ingelheim and Lilly Alliance in Diabetes has just presented a dissualFormative, Flora López and Josep Franch nothing.
“This is a resident -oriented training course, fundamentally R3 and R4, and young doctors, with less than ten years of MIR training on the new therapeutic options for the treatment of type 2 diabetes mellitus, according to the latest security studiescardiovascular published, ”they expose.
Specialists say that the treatment of diabetes has undergone important changes in recent years that force the professional to continuous training on the different molecules to be able to perform an individualized treatment to each patient.
Both López and Franch emphasize that it is logical that young doctors have less experience, hence they have tried to facilitate this process through an attractive online training with flexibility so they can help them in this path.
Among the concepts that should be clear to these professionals, they agree that an idea is that we are facing a pathology with a significant increase in prevalence due to changes in lifestyle.They emphasize that the treatment should be as intensive as possible in the early stages of the disease and in young patients, to delay the appearance of macro and microvascular complications, which worsens the quality of life and increases costs.
Doctors remember that until a few years ago the treatment of diabetes was limited to several families of drugs, such as metformin, sulfonylureas, glitazons and insulins.In recent years, Arsenal has been completed with new pharmacological groups that provide important benefits for patients: “cardiovascular security, little risk of hypoglycemia, weight reduction and benefits on other cardiovascular risk factors.
Among these new drugs, the incredines (inhibitors of the DPP-4 enzyme and analogues of the GLP-1 receptor and the SGLT2 inhibitors stand out.Within the insulins, they emphasize that there have also been news with new basal insulins and a biosimilar.
The specialists are convinced that the primary care doctor has important tools for the early diagnosis of diabetes and for treatment with multiple drug families that allow to draw a “custom suit” for each patient.They also have different diagnostic methods for the processing of complications, as explained by the spokesmen.
